Edwards Lifesciences.
American medical technology company
- Reports this week
- 6
- Active events
- 4
- Connections
- 78
What's happening
Active this week
-
Edwards Lifesciences and LabCorp successfully adopted AI to drive revenue growth.Some support3 reports
-
FDA issued an Early Alert regarding a device issue involving Edwards Lifesciences.Some support2 reports
-
Truist Financial set a $90.00 price target on Edwards Lifesciences shares, and TD Cowen reaffirmed its buy rating and raised the price objective.Well supported8 reports
-
Edwards Lifesciences maintains an office in Bangkok and has operated in Thailand for 25 years.Some support1 report
Earlier this month
One to three months ago
-
Truist Financial disclosed trading activity and issued price objective reports related to Edwards Lifesciences.Some support1 report
-
Wall Street Zen lowered its rating to 'hold' and BTIG raised its price objective to $110.00 for Edwards Lifesciences on August 26, 2026.Some support1 report
-
Edwards Lifesciences is using American Heart Association data to address heart disease and engage patients in India.Some support1 report
-
Gary Sorsher joined BDX from Edwards Lifesciences.Some support1 report
-
Citigroup bought a new position in shares of Edwards Lifesciences on August 5, 2026.Some support1 report
-
Jaime Wheeler was appointed CEO of CroíValve, which Bernard Collins chairs. Lucy O'Keeffe also joined as COO.Some support2 reports
-
CMS policy is reportedly affecting product adoption for Edwards Lifesciences, with a new CMS NCD policy expected in September.Some support2 reports
-
Edwards Lifesciences announced on July 23, 2026, that its Q2 financial results exceeded market expectations.Some support1 report
Gone quiet
No new reports in 90+ days-
SG Americas Securities LLC increased its position in Edwards Lifesciences shares, while a VP also sold company stock.Some support1 report
-
Both Edwards Lifesciences and Beta Bionics operate within the medical technology sector.Some support1 report
-
TD Cowen issued a buy rating and price target for Edwards Lifesciences, while Royal Bank of Canada reiterated its 'outperform' rating on the stock.Some support1 report
-
Edwards Lifesciences launched MITRIS in China in July 2025.Some support1 report
-
FTC intends to block an acquisition involving Edwards Lifesciences due to competitive concerns.Well supported6 reports
-
Natan highlighted a thesis on Substack regarding Edwards Lifesciences reaching a valuation comparable to Microsoft.Speculative1 report
-
The FDA approved the SAPIEN 3 TAVR therapy, while the company simultaneously faced removal from Russell indices.Speculative1 report
-
The FDA reviewed labeling definitions and transcatheter valve replacement technology, noting potential benefits from Trump-era tariffs for Abbott and Edwards Lifesciences.Some support1 report
-
Edwards Lifesciences reported a Return on Capital Employed (ROCE) of 13%, which is better than the industry average.Some support1 report
-
Edwards Lifesciences reported mid-single digit TAVR sales growth and market share rebalancing in Europe.Some support1 report
-
Edwards Lifesciences is based in Irvine, California, and serves patients across the United States.Some support3 reports
-
Edwards Lifesciences is headquartered in Irvine and utilizes LinkedIn for professional presence.Some support2 reports
-
Edwards Lifesciences develops products designed to treat advanced cardiovascular diseases.Some support2 reports1 development inside
-
Edwards Lifesciences updated guidelines on August 29, 2025, simplifying care pathways and showing EVOQUE's superior clinical benefit.Some support1 report
-
The United Nations projects that the aging population will drive increased demand for TAVR medical procedures.Well supported3 reports
No events began in the chosen period. Widen it, or reset.
Around Edwards Lifesciences this week
News at the entities that move Edwards Lifesciences most-
FDA StructuralCongress and the Senate are considering legislation affecting FDA submissions and drug patent rights.Moves Edwards Lifesciences
-
Medicare StructuralMedicare is providing subsidized mental health care services.Moves Edwards Lifesciences
-
SEC StructuralCelularity, Inc. filed with the SEC regarding its stock ownership on October 21, 2026.Moves Edwards Lifesciences
-
Federal Trade Commission OperationalNaomi Klein critiques oligarch power in tech companies while warning that AI economy debt financing risks a major crash.Moves Edwards Lifesciences
-
Royal Bank of Canada Mentioned togetherRoyal Bank of Canada, Citigroup, and Morgan Stanley issued price target and rating updates on August 27, 2026.Moves Edwards Lifesciences
-
CMS StructuralCMS approves and funds a health benefit while Hochul directs the department to consider ending it.Moves Edwards Lifesciences
Connections
The 30 strongest of 78, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA regulates Edwards Lifesciences, granting product approvals and issuing alerts regarding its medical devices.
-
Citigroup Transactional
Citigroup holds an investment position in Edwards Lifesciences and provides financial ratings.
-
Emmet Kelly Structural
Emmet Kelly serves as the Vice President and General Manager of Edwards Lifesciences.
-
European Society of Cardiology Operational
Edwards Lifesciences' trial results inform guideline updates set by the European Society of Cardiology.
-
Medicare Structural
Medicare coverage policies and standards dictate the market access and growth potential for Edwards Lifesciences.
-
SEC Structural
Edwards Lifesciences is subject to regulatory requirements by the SEC, specifically regarding the disclosure of trading activity.
-
Federal Trade Commission Operational
FTC is actively using its regulatory authority to challenge and block proposed acquisitions by Edwards Lifesciences due to competitive concerns.
-
Royal Bank of Canada Mentioned together
RBC provides investment ratings and price targets for Edwards Lifesciences stock.
Show all 30 connections
-
American Heart Association Structural
Edwards Lifesciences utilizes data collected by the American Heart Association to inform its work on heart disease.
-
CMS Structural
CMS policies structurally affect the market adoption and operational viability of Edwards Lifesciences' products.
-
Truist Financial Mentioned together
Truist Financial provides financial analysis and price targets for Edwards Lifesciences shares.
-
Leerink partners Operational
Leerink Partners provides market analysis, including rating changes and price targets, for Edwards Lifesciences.
-
TD Cowen Mentioned together
TD Cowen provides financial ratings and price targets for Edwards Lifesciences.
-
Boston Scientific Operational
Edwards Lifesciences and Boston Scientific are active competitors in the MedTech market, specifically regarding heart-valve systems.
-
Europe Shared context
Edwards Lifesciences operates and develops products within the European market, influenced by local guidelines and market dynamics.
-
BDX Transactional
A was the former employer of an individual who subsequently joined B.
-
LabCorp Operational
Both companies are leveraging AI adoption strategies to achieve revenue growth in the market.
-
Progress Operational
Edwards Lifesciences is conducting a clinical trial for Progress's TAVR product.
-
Barclays Mentioned together
Barclays provided investment ratings and target price increases for Edwards Lifesciences.
-
MarketBeat Mentioned together
MarketBeat reports and aggregates consensus stock ratings and target prices for Edwards Lifesciences.
-
Mizuho Mentioned together
Mizuho provides investment ratings and price objectives for Edwards Lifesciences.
-
Thailand Shared context
Edwards Lifesciences operates within the geographical context of Thailand.
-
Limerick Shared context
Edwards Lifesciences operates a site in Limerick that received an operational excellence award.
-
LinkedIn Mentioned together
Edwards Lifesciences uses LinkedIn as a platform for company presence and professional communication.
-
Irvine Shared context
Edwards Lifesciences is headquartered and operates out of the city of Irvine, California.
-
Bangkok Shared context
Edwards Lifesciences maintains an office presence in Bangkok.
-
Ireland Structural
Edwards Lifesciences maintains operational facilities across Ireland, relying on the country's infrastructure and regulatory environment.
-
Chicago Shared context
Edwards Lifesciences operates within Chicago and is recognized for driving measurable commercial outcomes.
-
London Mentioned together
Edwards Lifesciences was mentioned in an article discussing its participation in a global revenue effectiveness workshop.
-
Bernard Collins Mentioned together
No evidence was provided linking Bernard Collins and Edwards Lifesciences.
History
Events by the month they beganOctober 2026
3 eventsSeptember 2026
3 events- Edwards Lifesciences and InspireMD were compared in a market analysis.
- FDA approved expanded use of Sapien 3 valves, while Edwards conducts Progress trials and seeks expanded Medicare coverage for TAVR.
- Truist Financial disclosed trading activity and issued price objective reports related to Edwards Lifesciences.
August 2026
4 events- Wall Street Zen lowered its rating to 'hold' and BTIG raised its price objective to $110.00 for Edwards Lifesciences on August 26, 2026.
- Edwards Lifesciences is using American Heart Association data to address heart disease and engage patients in India.
- Gary Sorsher joined BDX from Edwards Lifesciences.
- Citigroup bought a new position in shares of Edwards Lifesciences on August 5, 2026.
Show 2 earlier months
July 2026
3 events- Jaime Wheeler was appointed CEO of CroíValve, which Bernard Collins chairs. Lucy O'Keeffe also joined as COO.
- CMS policy is reportedly affecting product adoption for Edwards Lifesciences, with a new CMS NCD policy expected in September.
- Edwards Lifesciences announced on July 23, 2026, that its Q2 financial results exceeded market expectations.
June 2026
16 events- Truist Financial set a $90.00 price target on Edwards Lifesciences shares, and TD Cowen reaffirmed its buy rating and raised the price objective.
- SG Americas Securities LLC increased its position in Edwards Lifesciences shares, while a VP also sold company stock.
- Both Edwards Lifesciences and Beta Bionics operate within the medical technology sector.
- TD Cowen issued a buy rating and price target for Edwards Lifesciences, while Royal Bank of Canada reiterated its 'outperform' rating on the stock.
- Edwards Lifesciences launched MITRIS in China in July 2025.
- FTC intends to block an acquisition involving Edwards Lifesciences due to competitive concerns.
- Natan highlighted a thesis on Substack regarding Edwards Lifesciences reaching a valuation comparable to Microsoft.
- The FDA approved the SAPIEN 3 TAVR therapy, while the company simultaneously faced removal from Russell indices.
- The FDA reviewed labeling definitions and transcatheter valve replacement technology, noting potential benefits from Trump-era tariffs for Abbott and Edwards Lifesciences.
- Edwards Lifesciences reported a Return on Capital Employed (ROCE) of 13%, which is better than the industry average.
- Edwards Lifesciences reported mid-single digit TAVR sales growth and market share rebalancing in Europe.
- Edwards Lifesciences is based in Irvine, California, and serves patients across the United States.
- Edwards Lifesciences is headquartered in Irvine and utilizes LinkedIn for professional presence.
- Edwards Lifesciences develops products designed to treat advanced cardiovascular diseases.
- Edwards Lifesciences updated guidelines on August 29, 2025, simplifying care pathways and showing EVOQUE's superior clinical benefit.
- The United Nations projects that the aging population will drive increased demand for TAVR medical procedures.